Insmed
OrganizationHeard in 9 episodes across 4 shows since Jan 2026
Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. Its work spans innovative medicines intended to address significant unmet medical needs.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 1 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 1 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 3 |
| Nov 2026 | 4 |
Email alert
Email me when Insmed comes up on a podcast
One email a week at most, with the new episodes that mention Insmed. Free, no account needed, unsubscribe in one click.
What experts have said about Insmed
1 statement · 1 positive
Insmed would be acquired or otherwise transact at a price above its current level.
“If something were to happen here, it happens higher than the current price it's trading at.”
Open the episode · Anthropic Jumps in Massive Debut, But Broad Markets Sell OffListen at 30:41
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
9 episodes featuring Insmed, newest first
- Nov 20, 2026
Nvidia sell-off exposes wider cracks in the AI tradeCNBC's "Fast Money"Nov 20, 2026 - Nov 20, 2026
Biotech weighs AI disruption against a stronger 2027 deal cycleBiotech HangoutNov 20, 2026 - Nov 19, 2026
Anthropic’s debut tests AI valuations as markets retreatCNBC's "Fast Money"Nov 19, 2026 - Nov 6, 2026
Election stakes meet biotech’s regulatory and pipeline risksBiotech HangoutNov 6, 2026 - Oct 20, 2026
Markets weigh Netflix weakness against AI infrastructure ambitionsCNBC's "Fast Money"Oct 20, 2026 - Oct 16, 2026
Biotech selloff tests valuations as clinical bets advanceBiotech HangoutOct 16, 2026